PubMed:33105485
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 38-46 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T2 | 126-134 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T3 | 137-146 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T4 | 342-350 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T5 | 469-477 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T6 | 707-715 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T7 | 774-782 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T8 | 937-945 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T9 | 1245-1252 | Disease | denotes | Obesity | http://purl.obolibrary.org/obo/MONDO_0011122 |
| T10 | 1257-1265 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
| T11 | 1375-1383 | Disease | denotes | diarrhea | http://purl.obolibrary.org/obo/MONDO_0001673 |
| T12 | 1508-1516 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T13 | 1596-1603 | Disease | denotes | obesity | http://purl.obolibrary.org/obo/MONDO_0011122 |
| T14 | 1617-1625 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
| T15 | 1670-1678 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T16 | 1812-1820 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T17 | 1857-1865 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T18 | 1908-1915 | Disease | denotes | obesity | http://purl.obolibrary.org/obo/MONDO_0011122 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 17-24 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T2 | 52-53 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T3 | 181-188 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T4 | 215-225 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | OBJECTIVES |
| T5 | 321-328 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T6 | 458-464 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T7 | 686-693 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T8 | 746-752 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T9 | 889-893 | http://purl.obolibrary.org/obo/UBERON_0003101 | denotes | male |
| T10 | 889-893 | http://www.ebi.ac.uk/efo/EFO_0000970 | denotes | male |
| T11 | 1319-1326 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T12 | 1410-1417 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T13 | 1477-1482 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T14 | 1714-1721 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T15 | 1757-1764 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
| T16 | 1823-1828 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
| T17 | 1921-1922 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 480-492 | Chemical | denotes | nucleic acid | http://purl.obolibrary.org/obo/CHEBI_33696 |
| T2 | 488-492 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
| T3 | 889-893 | Chemical | denotes | male | http://purl.obolibrary.org/obo/CHEBI_30780 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-84 | Sentence | denotes | Risk Factors for testing positive for SARS-CoV-2 in a national US healthcare system. |
| T2 | 85-96 | Sentence | denotes | BACKGROUND: |
| T3 | 97-214 | Sentence | denotes | Identifying risk factors for SARS-CoV-2 infection could help health systems improve testing and screening strategies. |
| T4 | 215-226 | Sentence | denotes | OBJECTIVES: |
| T5 | 227-353 | Sentence | denotes | Identify demographic factors, comorbid conditions, and symptoms independently associated with testing positive for SARS-CoV-2. |
| T6 | 354-361 | Sentence | denotes | DESIGN: |
| T7 | 362-398 | Sentence | denotes | Observational cross-sectional study. |
| T8 | 399-407 | Sentence | denotes | SETTING: |
| T9 | 408-439 | Sentence | denotes | Veterans Health Administration. |
| T10 | 440-449 | Sentence | denotes | PATIENTS: |
| T11 | 450-561 | Sentence | denotes | Persons tested for SARS-CoV-2 nucleic acid by polymerase chain reaction (PCR) between March 1 and May 14, 2020. |
| T12 | 562-575 | Sentence | denotes | MEASUREMENTS: |
| T13 | 576-718 | Sentence | denotes | Associations between demographic characteristics, diagnosed comorbid conditions, and documented symptoms with testing positive for SARS-CoV-2. |
| T14 | 719-727 | Sentence | denotes | RESULTS: |
| T15 | 728-798 | Sentence | denotes | Of 88,747 persons tested, 10,131 (11.4%) were SARS-CoV-2 PCR positive. |
| T16 | 799-1244 | Sentence | denotes | Positivity was associated with older age (≥80 vs. <50 years: aOR 2.16, 95% CI 1.97-2.37), male sex (aOR 1.45, 95% CI 1.34-1.57), regional SARS-CoV-2 burden (≥2,000 vs. <400 cases/million: aOR 5.43, 95% CI 4.97-5.93), urban residence (aOR 1.78, 95% CI 1.70-1.87), Black (aOR 2.15, 95% CI 2.05-2.26) or American Indian/Alaska Native/Pacific Islander (aOR 1.26, 95% CI 1.05-1.52) vs. White race, and Hispanic ethnicity (aOR 1.52, 95% CI 1.40-1.65). |
| T17 | 1245-1336 | Sentence | denotes | Obesity and diabetes were the only two medical conditions associated with testing positive. |
| T18 | 1337-1427 | Sentence | denotes | Documented fevers, chills, cough, and diarrhea were also associated with testing positive. |
| T19 | 1428-1633 | Sentence | denotes | The population attributable fraction of positive tests was highest for regional SARS-CoV-2 burden (35.3%), followed by demographic variables (27.2%), symptoms (12.0%), obesity (10.5%), and diabetes (0.4%). |
| T20 | 1634-1646 | Sentence | denotes | LIMITATIONS: |
| T21 | 1647-1774 | Sentence | denotes | Lack of information on SARS-CoV-2 exposures or the indications for testing which may affect the likelihood of testing positive. |
| T22 | 1775-1786 | Sentence | denotes | CONCLUSION: |
| T23 | 1787-1973 | Sentence | denotes | The majority of positive SARS-CoV-2 tests were attributed to regional SARS-CoV-2 burden, demographic characteristics and obesity with a minor contribution of chronic comorbid conditions. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 1245-1252 | Phenotype | denotes | Obesity | http://purl.obolibrary.org/obo/HP_0001513 |
| T2 | 1356-1362 | Phenotype | denotes | chills | http://purl.obolibrary.org/obo/HP_0025143 |
| T3 | 1364-1369 | Phenotype | denotes | cough | http://purl.obolibrary.org/obo/HP_0012735 |
| T4 | 1375-1383 | Phenotype | denotes | diarrhea | http://purl.obolibrary.org/obo/HP_0002014 |
| T5 | 1596-1603 | Phenotype | denotes | obesity | http://purl.obolibrary.org/obo/HP_0001513 |
| T6 | 1908-1915 | Phenotype | denotes | obesity | http://purl.obolibrary.org/obo/HP_0001513 |